Mycoplasma Testing Market Highlights:

The Mycoplasma Testing Market is expected to grow significantly CAGR of 13.9% and market held a value of USD 2.18 billion over the forecast period 2022-2030.

Mycoplasma testing used to detect contamination in given biologic sample.

Increasing R&D investment and new product launches are expected to drive the growth of market. On other hand, the available of alternative traditional method can restrain the market growth over the assessment period.

Regional Analysis:

Geographically, the Americas is expected to dominate the global market owing to the presence of well-established players and growth in pharmaceutical and medical device companies. Europe is expected to hold the second largest position in the global market. Asia-Pacific is expected to be the fastest growing market owing to the increasing adoption of the technologies. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global market.

Segmentation:

The global mycoplasma testing market has been segmented into product, Technique, application, and end user.

Based on product, market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is expected to account for the largest share and fastest growing segment of the global market.

Based on technique, market is segmented into Enzyme-based, PCR, ELISA, Direct Assay, Indirect Assay, Others.

Based on application, has been segmented into cell line and cell therapy testing, virus testing, row material testing, lot release testing, and others.

Based on end user, has been segmented into pharmaceutical and biological manufacturing, contract research organizations, cell banks, and others

Key Players:

Some of the prominent mycoplasma testing market players are Charles River Laboratories, Inc., Merck KGaA, Lonza Group Ltd, Roche Diagnostics, SGS S.A., American Type Culture Collection, Invivogen, Wuxi Apptec, Promocell GmbH, and Thermo Fisher Scientific Inc.